Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCGP 3466B maleate is an orally active glyceraldehyde-3-phosphate dehydrogenase (GAPDH) inhibitor. Exhibits antiapoptotic activity via inhibition of GAPDH nuclear translocation and mitochondrial complex 1-dependent H2O2 release. CGP 3466B inhibits colon cancer proliferation in vitro and displays neuroprotective activity in vivo.
CGP 3466B maleate is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.
M. Wt | 391.42 |
Formula | C19H17NO.C4H4O4 |
Storage | Store at +4°C |
Purity | ≥99% (HPLC) |
CAS Number | 200189-97-5 |
PubChem ID | 9821821 |
InChI Key | SQAZQLMBEHYFJA-BTJKTKAUSA-N |
Smiles | O=C(O)/C=C\C(O)=O.CN(CC#C)CC2=CC1=CC=CC=C1OC3=C2C=CC=C3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
water | 3.91 | 10 | |
DMSO | 39.14 | 100 |
The following data is based on the product molecular weight 391.42. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.55 mL | 12.77 mL | 25.55 mL |
5 mM | 0.51 mL | 2.55 mL | 5.11 mL |
10 mM | 0.26 mL | 1.28 mL | 2.55 mL |
50 mM | 0.05 mL | 0.26 mL | 0.51 mL |
References are publications that support the biological activity of the product.
Andringa et al (2003) TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. Neurobiol.Dis. 14 205 PMID: 14572443
Sagot et al (2000) An orally active anti-apoptotic molecule (CGP 3466B) preserves mitochondria and enhances survival in an animal model of motoneuron disease. Br.J.Pharmacol. 131 721 PMID: 11030721
Zoccarato et al (2008) Clorgyline and other propargylamine derivatives as inhibitors of succinate-dependent H2O2 release at NADH:UBIQUINONE oxidoreductase (Complex I) in brain mitochondria. J.Bioenerg.Biomembr. 40 289 PMID: 18763029
Bazzocco et al (2015) Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment. Clin.Cancer Res. 21 3685 PMID: 25944804
If you know of a relevant reference for CGP 3466B maleate, please let us know.
Keywords: CGP 3466B maleate, CGP 3466B maleate supplier, glyceraldehyde-3-phosphate, dehydrogenase, GAPDH, inhibitors, inhibits, CGP3466B, TCH346, TCH, 346, maleate, Other, Dehydrogenases, 2966, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for CGP 3466B maleate include:
Xu et al (2013) Behavioral effects of cocaine mediated by nitric oxide-GAPDH transcriptional signaling. Neuron 78 623 PMID: 23719162
Do you know of a great paper that uses CGP 3466B maleate from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review CGP 3466B maleate and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.